^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Fycompa (perampanel)

    i
    Other names: E2007, E-2007, ER 155055 90
    Associations

    News

    Trials
    Company:
    Catalyst Pharma, Eisai, Grupo Biotoscana
    Drug class:
    AMPA receptor antagonist
    Associations

    News

    Trials
    2ms
    SENIPERA: Senicapoc and Perampanel for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Aarhus University Hospital
    New P1 trial
    |
    Fycompa (perampanel)
    3ms
    EPIPOP: Population Pharmacokinetics of Antiepileptic in Pediatrics (clinicaltrials.gov)
    P=N/A, N=753, Completed, Assistance Publique - Hôpitaux de Paris | Recruiting --> Completed
    Trial completion
    |
    Fycompa (perampanel)
    4ms
    Perampanel Oral Suspension in the Treatment of Young Children with Epilepsy: A Multicenter Prospective Observational Study (ChiCTR2500109538)
    P4, N=122, Not yet recruiting, Peking University First Hospital; Peking University First Hospital
    New P4 trial
    |
    Fycompa (perampanel)
    4ms
    Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus (clinicaltrials.gov)
    P4, N=1, Terminated, Wayne State University | N=25 --> 1 | Trial completion date: Jan 2028 --> Oct 2025 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Oct 2025; Study was not initiated.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Fycompa (perampanel)
    7ms
    SUPER-CAT: Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, University of Milano Bicocca | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Fycompa (perampanel)
    8ms
    Perampanel for the prevention of post-stroke epilepsy- efficacy and safety (ACTRN12618001984280)
    P2, N=164, Active, not recruiting, Alfred Health | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Fycompa (perampanel)
    8ms
    A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy (clinicaltrials.gov)
    P2, N=100, Recruiting, Eisai Inc. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Fycompa (perampanel)
    9ms
    Update of clinical management in autoimmune encephalitis-2004 (PubMed, Rinsho Shinkeigaku)
    3) Treatment trends for rituximab-resistant refractory cases include tocilizumab (IL6 receptor monoclonal antibody) and bortezomib (26S proteasome inhibitor). On the other hand, new Na channel inhibitors (lacosamide, etc.) and perampanel may be useful for treating symptomatic epilepsy in AE.
    Journal
    |
    IL6 (Interleukin 6)
    |
    Rituxan (rituximab) • bortezomib • Actemra IV (tocilizumab) • Fycompa (perampanel)
    12ms
    A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures (clinicaltrials.gov)
    P4, N=125, Completed, Eisai Korea Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Apr 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Fycompa (perampanel)
    1year
    Clinical efficacy analysis of perampanel in patients with epilepsy comorbid sleep disorders (ChiCTR2400093593)
    P4, N=72, Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University
    New P4 trial
    |
    Fycompa (perampanel)
    1year
    A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures (clinicaltrials.gov)
    P=N/A, N=110, Recruiting, Eisai Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Fycompa (perampanel)
    1year
    SUPER-CAT: Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, University of Milano Bicocca | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    Fycompa (perampanel)